Psoriasis — Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence
Citation(s)
A Phase IV Open Label, Multicentre, Investigational Study of the Therapeutic Options for Subjects Discontinuing Efalizumab Therapy and Experiencing Inflammatory Disease Recurrence